반응식
[C:1]([O:5][C:6](=[O:23])[NH:7][C:8]1[S:9][CH:10]=[C:11]([CH2:13][S:14][C:15]2[CH:20]=[CH:19][C:18]([Cl:21])=[CH:17][C:16]=2[NH2:22])[N:12]=1)([CH3:4])([CH3:3])[CH3:2].[O:24]1[C:28]2[CH:29]=[CH:30][CH:31]=[CH:32][C:27]=2[CH:26]=[C:25]1[S:33](Cl)(=[O:35])=[O:34]>N1C=CC=CC=1>[C:1]([O:5][C:6](=[O:23])[NH:7][C:8]1[S:9][CH:10]=[C:11]([CH2:13][S:14][C:15]2[CH:20]=[CH:19][C:18]([Cl:21])=[CH:17][C:16]=2[NH:22][S:33]([C:25]2[O:24][C:28]3[CH:29]=[CH:30][CH:31]=[CH:32][C:27]=3[CH:26]=2)(=[O:34])=[O:35])[N:12]=1)([CH3:4])([CH3:2])[CH3:3]참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
Following General Procedure B, the title compound (380 mg, 54%) was prepared from tert-butyl(4-{[(2-amino-4-chlorophenyl)thio]methyl}-1,3-thiazol-2-yl)carbamate (640 mg, 1.72 mmol) and 1-benzofuran-2-sulfonyl chloride (372 mg, 1.72 mmol) in pyridine (5 ml).
출처 및 근거
- ORD 기록
- ord-a55ebd70f9964bb5a7307e39ca9b2f02
- 출처 데이터셋
- uspto-grants-2014_07
- 특허 번호
- US08791161B2
연결된 노트
불러오는 중…